Affiliations 

  • 1 Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
  • 2 College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
  • 3 College of Medicine, King Saud University, Riyadh, Saudi Arabia
  • 4 Ritme Consultancy, Rotterdam, The Netherlands
  • 5 College of Arts and Sciences, University of Alabama at Birmingham, Birmingham, AL, USA
  • 6 Liver Transplant Centre, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
Obes Rev, 2022 Jul;23(7):e13448.
PMID: 35338558 DOI: 10.1111/obr.13448

Abstract

Saudi Arabia (SA) has a reported obesity prevalence greater than the global average. Here, we systematically review firstly the prevalence and associated factors (59 studies) and secondly the pharmacological, lifestyle, and surgical interventions for obesity (body mass index, >30 kg/m2 ) in SA (29 studies) between December 2020 and March 2021 in PubMed, Medline, Embase, PsycINFO, and Cochrane. Peer-reviewed articles in Arabic and English on human adults (aged >18 years) were searched. Among the eight largest studies with sample sizes over 10,000 people, the maximum-reported obesity prevalence was 35.6%, with notable variations in gender and geographic region. Diet, specifically the move towards Western diet and heavy consumption of sugary beverages, and high levels of inactivity are major contributing factors to obesity. The reported obesity-risk polymorphisms are not specific. Bariatric surgery is underrepresented, and in general, there is a lack of nationally coordinated studies on weight loss interventions. In particular, the systematic review did not find a body of research on psychological interventions. There is no trial data for the use of GLP-1 analogs in SA, despite their widespread use. These findings can help policymakers, and practitioners prioritize future research efforts to reduce obesity prevalence in SA.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.